Acquired drug resistance by Mycobacterium tuberculosis (MTB) may result in treatment
failure and death. Bedaquiline was recently approved for the treatment of multidrug-resistant …

Bedaquiline is recommended by the World Health Organization for the treatment of
multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). We …

The European Respiratory Journal has recently discussed delamanid and bedaquiline and
their use in difficult-to-treat cases affected by multidrug-resistant tuberculosis (MDR-TB) or …

Introduction: In recent years, a pressing need to develop new, effective and safe drugs
against tuberculosis (TB) has continued. Poor adherence to a long therapeutic regimen …

BACKGROUND: The World Health Organization recommends adding bedaquiline or
delamanid to multidrug-resistant tuberculosis (MDR-TB) regimens for which four effective …

Background This retrospective cohort study assessed benefits and risks of bedaquiline
treatment in multidrug-resistant-tuberculosis (MDR-TB) combination therapy by evaluating …

Objective: Multidrug-resistant tuberculosis (MDR-TB) is a life-threatening infectious disease.
Treatment requires multiple antimicrobial agents used for extended periods of time. The …

Relatively little is known about the efficacy and safety of the programmatic use of
bedaquiline and delamanid in multidrug-resistant tuberculosis (MDR-TB) treatment. This …

Treatment of multidrug-resistant tuberculosis (MDR-TB) is hindered by limited efficacy and
significant toxicity of second-line drugs. The need for new therapeutic options is critical to …

South African patients with rifampicin-resistant tuberculosis (TB) and resistance to
fluoroquinolones and/or injectable drugs (extensively drug-resistant (XDR) and preXDR-TB) …